Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AZD-0364

Catalog No: tcsc0042190

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Specifications

CAS No:
2097416-76-5

Formula:
$C_{24}H_{24}F_2N_8O_2$

Pathway:
Stem Cell/Wnt;MAPK/ERK Pathway

Target:
ERK;ERK

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (202.22 mM)

Observed Molecular Weight:
494.5

Product Description

AZD-0364 is a potent and selective **ERK2** inhibitor extracted from patent WO2017080979A1, compound example 18, has an **IC_{50}** of

0.6 nM.

IC50 & Target: IC50: 0.6 nM (ERK2)[1]

In Vitro: AZD-0364 is measured in the ERK2 mass spectrometry and A375 phospho-p90RSK assays with IC_{50}s of 0.6 nM and 5.7 nM, respectively. AZD-0364 can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as a monotherapy and this effect is synergistically enhanced by treatment with Selumetinib[1].

In Vivo: Tumor growth inhibition by AZD-0364 ethanesulfonic acid (Example 18a) in combination with MEK inhibitor Selumetinib is measured. Studies are performed in the A549 xenograft model. Selumetinib is dosed twice daily (BiD) 8 hours apart and AZD-0364 ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and AZD-0364 ethanesulfonic acid reduce tumor growth relative to vehicle only control. The combination of Selumetinib and AZD-0364 ethanesulfonic acid results in a reduction in tumor growth[1].